Atorvastatin seemed to exert a positive action in monocrotaline-induced PAH by reducing the levels of glycogen synthase kinase-3β and sterol regulatory element-binding protein 1 and increasing the levels of hexokinase 2 and carnitine palmitoyltransferase I [82]. This evidence concerns the gene SREBF1 and pulmonary arterial hypertension.